OSU as a Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

基本信息

批准号：
10356923
负责人：
DAVID P. CARBONE
金额：
$ 108.37万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-28 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10356923
关键词：
Address Adult Advisory Committees Affect Area Award Basic Science Biochemistry Biological Markers Biomedical Research Biometry Biotechnology CEBPA gene Cancer Biology Cancer Center Cancer Hospital Cancer Patient Center for Translational Science Activities Clinic Clinical Clinical Data Clinical Investigator Clinical Oncology Supplement (K12)Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Comprehensive Cancer Center Contracts Data Databases Decitabine Discipline Disease Education Educational process of instructing Educational workshop Enrollment Environment Epidemiologist FLT3 gene Faculty Fostering Funding Generations Goals Grant Growth Gynecologic Oncology Health Personnel Hematologic Neoplasms Hematology Hematopoietic Neoplasms Image Immunologics Immunology Infrastructure Inpatients Institutes Investigational Therapies Knowledge Laboratory Scientists Lead Leadership Learning Malignant Neoplasms Medical Medical Oncology Mentors Modeling Molecular Genetics NCI Center for Cancer Research National Clinical Trials Network Nurses Oblimersen Ohio Operative Surgical Procedures Outcome Outpatients Pathologist Patient-Focused Outcomes Patients Peer Review Pentostatin Performance Pharmacists Pharmacology Phase Physicians Postdoctoral Fellow Protocols documentation Psychiatrist Quality of life Radiation Oncologist Radiation Oncology Radiation therapy Research Research Activity Research Design Research Institute Research Personnel Resources Science Scientist Site Solid Neoplasm Structure Support Groups Surgical Oncologist Surgical Oncology Symptoms Therapeutic Therapeutic Agents Time Tissues Toxic effect Training Translating Translational trial Tumor Biology Universities base cancer clinical trial cancer prevention cancer therapy career career development college confirmatory trial data submission design doctoral student drug development efficacy evaluation experience high standard improved improved outcome innovation investigator-initiated trial lenalidomide leukemia meetings minority patient multidisciplinary multimodality next generation novel novel therapeutics operation patient population pre-clinical pre-doctoral preclinical study programs recruit research study risk stratification rituximab success targeted treatment translational scientist translational therapeutics treatment trial tumor heterogeneity volunteer

项目摘要

PROJECT SUMMARY The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU) participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching and mentoring within the NCTN, and 9) enroll volunteering patients on trials.

项目摘要该申请的目的是提供基础设施以支持俄亥俄州立大学（OSU）参与NCI NCTN计划的科学和临床研究活动，作为网络领导学术参与地点（OSU-LAPS）。 OSU的教师被整合到科学和行政上活动，参加会议，管理多个核心实验室，设计研究并参与所有现有的患者使用OSU综合癌症中心（OSUCCC）资源来利用小组的成人NCTN网络组资源。 OSUCCC研究人员正在开发和领导研究，旨在注册患者多学科的研究治疗试验以及开发和执行相关科学研究研究，引起特殊血液学恶性肿瘤和实体瘤方面的专业知识。我们的医学，血液学，外科和辐射肿瘤学家，移植者，精神科医生，病理学家，细胞遗传学家，转化和基本实验室科学家，统计学家，流行病学家，护士，药剂师和临床研究协调员有助于构架临床和基础科学问题的答案有助于改善患者的结果，并了解肿瘤生物学。 OSU-LAPS将为OSU患者群体提供创新的NCI试验，支持有关肿瘤生物学，找到更好治疗的科学发现，并提高患者的生活质量改善影响成年人的癌症范围的结果。这个全面的计划的目的是：1）研究新的治疗剂及其对III NCI临床试验的毒性； 2）评估功效基于临床前数据的新型组合的毒性和更有效地利用协同组合的毒性； 3）使用手术，免疫学和放射性疗法开发多模式方法组合； 4）整合分子遗传学，生物化学，药理学，免疫学和治疗方案设计和执行中的生物统计学； 5）通过发现改善癌症结果以及博士后学生，护士，联盟医务人员和医生的教育，6）了解并利用肿瘤异质性充分利用目标疗法的价值，7）与癌症相关的症状，8）形成下一代临床研究者，通过提供正式教学并在NCTN中进行指导，以及9）参加试验的志愿患者。